Literature DB >> 9851894

alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.

M J Heeb1, F España.   

Abstract

Human glandular kallikrein (hK2) is a possible new marker for prostate cancer that is homologous to prostate specific antigen. Purified hK2 added to serum or plasma reacted with endogenous protease inhibitors to form complexes of >350, 135, and 80 kDa, and some hK2 remained free, as judged by immunoblotting. The former two complexes could be removed by specific antibodies to alpha2-macroglobulin and to C1- inactivator, respectively, and they comigrated on SDS-PAGE with complexes formed between hK2 and purified alpha2-macroglobulin or C1-inactivator. hK2 complexes of 80 kDa could not be completely removed with any anti-serpin antibody used. Thus, these may consist of more than one type of hK2 complex. In contrast, essentially all hK2 complexes were removed from seminal plasma by antibody to protein C inhibitor, demonstrating that protein C inhibitor is the only significant inhibitor of hK2 in semen. hK2 reacted more rapidly with alpha2-macroglobulin than with any other inhibitor in plasma or serum. Divalent metal ions and heparin did not appreciably affect the rate of formation of any of the hK2 complexes in serum or plasma or with purified alpha2-macroglobulin or C1-inactivator. Measurement of one or more of the hK2 forms identified here may have diagnostic or prognostic potential for prostate cancer. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851894     DOI: 10.1006/bcmd.1998.0209

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  4 in total

Review 1.  The Cancer Genome Anatomy Project: EST sequencing and the genetics of cancer progression.

Authors:  D B Krizman; L Wagner; A Lash; R L Strausberg; M R Emmert-Buck
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 2.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

3.  Proteolytic processing of angiotensin-I in human blood plasma.

Authors:  Diana Hildebrand; Philipp Merkel; Lars Florian Eggers; Hartmut Schlüter
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

4.  Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Authors:  Jon A Kenniston; Ryan R Faucette; Diana Martik; Stephen R Comeau; Allison P Lindberg; Kris J Kopacz; Gregory P Conley; Jie Chen; Malini Viswanathan; Niksa Kastrapeli; Janja Cosic; Shauna Mason; Mike DiLeo; Jan Abendroth; Petr Kuzmic; Robert C Ladner; Thomas E Edwards; Christopher TenHoor; Burt A Adelman; Andrew E Nixon; Daniel J Sexton
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.